ArticlePharmaceutics2025

Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice.

Vinícius Monteagudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.